DOXIMITY INC-CLASS A (DOCS)
US26622P1075 - Common Stock
DOCS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. DOCS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DOCS is growing strongly while it is still valued neutral. This is a good combination! This makes DOCS very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
In the past year DOCS had a positive cash flow from operations.
Each year in the past 5 years DOCS has been profitable.
In the past 5 years DOCS always reported a positive cash flow from operatings.
1.2 Ratios
DOCS has a Return On Assets of 15.57%. This is amongst the best in the industry. DOCS outperforms 97.22% of its industry peers.
The Return On Equity of DOCS (18.11%) is better than 97.22% of its industry peers.
DOCS has a Return On Invested Capital of 16.83%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 6.38%.
The 3 year average ROIC (12.02%) for DOCS is below the current ROIC(16.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.57% | ||
| ROE | 18.11% | ||
| ROIC | 16.83% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
1.3 Margins
With an excellent Profit Margin value of 33.69%, DOCS belongs to the best of the industry, outperforming 97.22% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
Looking at the Operating Margin, with a value of 39.06%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Operating Margin has improved in the last couple of years.
The Gross Margin of DOCS (89.94%) is better than 97.22% of its industry peers.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.06% | ||
| PM (TTM) | 33.69% | ||
| GM | 89.94% |
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for DOCS has been reduced compared to 1 year ago.
Compared to 5 years ago, DOCS has more shares outstanding
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 41.35 indicates that DOCS is not in any danger for bankruptcy at the moment.
DOCS has a Altman-Z score of 41.35. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 41.35 |
ROIC/WACC1.82
WACC9.27%
2.3 Liquidity
A Current Ratio of 7.24 indicates that DOCS has no problem at all paying its short term obligations.
With an excellent Current ratio value of 7.24, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS has a Quick Ratio of 7.24. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of DOCS (7.24) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.24 | ||
| Quick Ratio | 7.24 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.94%, which is quite impressive.
The Earnings Per Share has been growing by 81.49% on average over the past years. This is a very strong growth
DOCS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.27%.
DOCS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.87% yearly.
EPS 1Y (TTM)34.94%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)15.27%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%20.44%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.57% yearly.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.03% yearly.
EPS Next Y21.48%
EPS Next 2Y14.53%
EPS Next 3Y15.21%
EPS Next 5Y13.57%
Revenue Next Year14.47%
Revenue Next 2Y11.99%
Revenue Next 3Y11.42%
Revenue Next 5Y11.03%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 51.63, DOCS can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 75.00% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.73. DOCS is valued rather expensively when compared to this.
A Price/Forward Earnings ratio of 46.40 indicates a quite expensive valuation of DOCS.
DOCS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 72.22% of the companies in the same industry.
DOCS is valuated expensively when we compare the Price/Forward Earnings ratio to 22.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.63 | ||
| Fwd PE | 46.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DOCS is valued a bit cheaper than 66.67% of the companies in the same industry.
DOCS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 63.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.68 | ||
| EV/EBITDA | 41.83 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
DOCS has an outstanding profitability rating, which may justify a higher PE ratio.
DOCS's earnings are expected to grow with 15.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.4
PEG (5Y)N/A
EPS Next 2Y14.53%
EPS Next 3Y15.21%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DOXIMITY INC-CLASS A
NYSE:DOCS (12/20/2024, 8:05:43 PM)
After market: 58.5 +0.67 (+1.16%)57.83
+2.65 (+4.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners61.97%
Inst Owner Change1.43%
Ins Owners10.56%
Ins Owner Change1.34%
Market Cap10.80B
Analysts73.6
Price Target57.54 (-0.5%)
Short Float %5.96%
Short Ratio3.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.72%
Min EPS beat(2)15.86%
Max EPS beat(2)23.58%
EPS beat(4)4
Avg EPS beat(4)21.54%
Min EPS beat(4)15.86%
Max EPS beat(4)24.29%
EPS beat(8)8
Avg EPS beat(8)21.05%
EPS beat(12)12
Avg EPS beat(12)30.2%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.53%
Min Revenue beat(2)3.56%
Max Revenue beat(2)5.51%
Revenue beat(4)3
Avg Revenue beat(4)3.13%
Min Revenue beat(4)-0.57%
Max Revenue beat(4)5.51%
Revenue beat(8)5
Avg Revenue beat(8)1.68%
Revenue beat(12)8
Avg Revenue beat(12)2.18%
Revenue beat(16)10
Avg Revenue beat(16)-0.11%
PT rev (1m)51.59%
PT rev (3m)65.92%
EPS NQ rev (1m)14.95%
EPS NQ rev (3m)12.62%
EPS NY rev (1m)6.78%
EPS NY rev (3m)8.07%
Revenue NQ rev (1m)6.09%
Revenue NQ rev (3m)6.77%
Revenue NY rev (1m)3.26%
Revenue NY rev (3m)4.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.63 | ||
| Fwd PE | 46.4 | ||
| P/S | 20.89 | ||
| P/FCF | 49.68 | ||
| P/OCF | 48.29 | ||
| P/B | 11.23 | ||
| P/tB | 12.44 | ||
| EV/EBITDA | 41.83 |
EPS(TTM)1.12
EY1.94%
EPS(NY)1.25
Fwd EY2.15%
FCF(TTM)1.16
FCFY2.01%
OCF(TTM)1.2
OCFY2.07%
SpS2.77
BVpS5.15
TBVpS4.65
PEG (NY)2.4
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.57% | ||
| ROE | 18.11% | ||
| ROCE | 20.47% | ||
| ROIC | 16.83% | ||
| ROICexc | 91.88% | ||
| ROICexgc | 189.64% | ||
| OM | 39.06% | ||
| PM (TTM) | 33.69% | ||
| GM | 89.94% | ||
| FCFM | 42.05% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
ROICexc(3y)87.69%
ROICexc(5y)N/A
ROICexgc(3y)180.49%
ROICexgc(5y)N/A
ROCE(3y)14.62%
ROCE(5y)21.23%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-48.43%
ROICexc growth 5YN/A
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 61.02% | ||
| Cap/Sales | 1.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 105.39% | ||
| Profit Quality | 124.83% | ||
| Current Ratio | 7.24 | ||
| Quick Ratio | 7.24 | ||
| Altman-Z | 41.35 |
F-Score9
WACC9.27%
ROIC/WACC1.82
Cap/Depr(3y)76.9%
Cap/Depr(5y)164.34%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2.04%
Profit Quality(3y)121.74%
Profit Quality(5y)186.38%
High Growth Momentum
Growth
EPS 1Y (TTM)34.94%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y21.48%
EPS Next 2Y14.53%
EPS Next 3Y15.21%
EPS Next 5Y13.57%
Revenue 1Y (TTM)15.27%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%20.44%
Revenue Next Year14.47%
Revenue Next 2Y11.99%
Revenue Next 3Y11.42%
Revenue Next 5Y11.03%
EBIT growth 1Y41.49%
EBIT growth 3Y47.72%
EBIT growth 5Y90.21%
EBIT Next Year27.97%
EBIT Next 3Y16.32%
EBIT Next 5Y15.44%
FCF growth 1Y44.03%
FCF growth 3Y31.5%
FCF growth 5Y66.11%
OCF growth 1Y40.97%
OCF growth 3Y30.41%
OCF growth 5Y64.46%